|
CN
|
MCI
|
ADD
|
ND
|
CI
|
PiB–
|
PiB+
|
All
|
---|
(n = 215)
|
(n = 79)
|
(n = 59)
|
(n = 294)
|
(n = 138)
|
(n = 253)
|
(n = 100)
|
(n = 353)
|
---|
MPP-Aβ42
|
P = 0.7982
|
**P < 0.01
|
P = 0.3132
|
P = 0.9827
|
P = 0.1125
|
P = 0.9750
|
P = 0.7965
|
P = 0.1776
|
r = 0.0175
|
r = 0.3479
|
r = –0.1336
|
r = –0.0012
|
r = 0.1357
|
r = 0.0020
|
r = –0.0261
|
r = –0.0719
|
MPP-Aβ40
|
*P = 0.0301
|
**P < 0.01
|
P = 0.6639
|
***P < 0.001
|
**P < 0.01
|
P = 0.8155
|
P = 0.2436
|
****P < 0.0001
|
r = 0.1479
|
r = 0.2950
|
r = 0.0578
|
r = 0.2177
|
r = 0.2272
|
r = –0.0147
|
r = 0.1177
|
r = 0.2309
|
MPP-Aβ42/40
|
#
P = 0.0940
|
P = 0.6395
|
P = 0.2868
|
**P < 0.01
|
P = 0.6488
|
P = 0.7416
|
P = 0.4437
|
****P < 0.0001
|
r = –0.1145
|
r = 0.0535
|
r = –0.1410
|
r = –0.1654
|
r = –0.0391
|
r = –0.0208
|
r = –0.0775
|
r = –0.2280
|
-
SUVR standard uptake value ratio, MPP-Aβ MPP-treated plasma β-amyloid, CN cognitively normal, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia, ND nondemented group (CN plus MCI), CI cognitively impaired group (MCI plus ADD), PiB– or PiB+ subjects with negative or positive amyloid deposition, All complete study cohort
- *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 and Pearson r values by Pearson’s correlation analysis (two-tailed)
-
#
P < 0.10, trend toward significance